Curia (formerly AMRI) to Acquire Integrity Bio, Inc.

BioSelective Capital Investments Acquires BioDuro's Irvine Drug Product Operations to Form Forma Life Sciences

February 4, 2026

Pharmaceuticals

BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.

Curi Bio Acquires South Korea-based Quvit Bio

January 12, 2026

Biotechnology

Curi Bio completed a full acquisition of South Korea-based Quvit Bio and has established Curi Bio Co., Ltd. as its Asia-Pacific commercial and operational hub. The deal integrates Quvit's imaging hardware, software and team to expand Curi Bio's localized sales, R&D and operational capabilities across South Korea, Japan and China.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities

February 14, 2022

Biotechnology

Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.

Curi Bio Acquires Dana Solutions

July 23, 2020

Biotechnology

Curi Bio, a Seattle-based developer of human iPSC platforms for drug discovery, has acquired Dana Solutions to integrate Dana's AI/ML platforms (PhenoLearn, Pulse, PhenoTox) into Curi's human cell- and tissue-based discovery and safety-testing offerings. The deal (terms undisclosed) will allow Curi to offer combined predictive human iPSC-derived models and AI-enabled phenotypic data insights and will continue a prior FDA-funded collaboration to validate PhenoTox.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.